Standard Biotools (LAB) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.63, -4.70% vs the prior close of $0.66.
- Volume 647.31K shares, 0.5x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
LAB slides 4.7% to $0.63, a 52-week low. Closed at $0.63, -4.70% vs the prior close of $0.66. Day range $0.63–$0.66, opened at $0.66.
LAB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — LAB slides 4.7% to $0.63, a 52-week low
- Closed at $0.63, -4.70% vs the prior close of $0.66. Day range $0.63–$0.66, opened at $0.66.
- Volume was 647.31K shares, 0.5x its 50-day average of 1.30M — lighter than usual.
- Price is -10.3% vs its 50-day average ($0.70) and -34.2% vs its 200-day average ($0.96).
- 52-week range $0.63–$1.72; today's close sits at 0% of that range, 63.4% below the 52-week high.
Oct 15, 2026 — LAB jumps 4.8% to $0.66
- Closed at $0.66, +4.76% vs the prior close of $0.63. Day range $0.63–$0.67, opened at $0.63.
- Volume was 485.70K shares, 0.4x its 50-day average of 1.34M — lighter than usual.
- Price is -6.3% vs its 50-day average ($0.70) and -31.1% vs its 200-day average ($0.96).
- 52-week range $0.63–$1.72; today's close sits at 3% of that range, 61.6% below the 52-week high.
Oct 14, 2026 — LAB slides 4.5% to $0.63, a 52-week low, 3 down days in a row
- Closed at $0.63, -4.55% vs the prior close of $0.66. Day range $0.63–$0.68, opened at $0.64.
- Volume was 1.19M shares, 0.9x its 50-day average of 1.34M.
- Price is -10.9% vs its 50-day average ($0.71) and -34.5% vs its 200-day average ($0.96).
- 52-week range $0.63–$1.72; today's close sits at 0% of that range, 63.4% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — LAB ends flat (+0.0%) to $0.66
- Closed at $0.66, +0.00% vs the prior close of $0.66. Day range $0.65–$0.67, opened at $0.66.
- Volume was 368.90K shares, 0.3x its 50-day average of 1.36M — lighter than usual.
- Price is -7.1% vs its 50-day average ($0.71) and -31.6% vs its 200-day average ($0.97).
- 52-week range $0.63–$1.72; today's close sits at 3% of that range, 61.6% below the 52-week high.
Oct 12, 2026 — LAB slides 4.3% to $0.66, a 1-month low
- Closed at $0.66, -4.35% vs the prior close of $0.69. Day range $0.65–$0.69, opened at $0.69.
- Volume was 494.60K shares, 0.4x its 50-day average of 1.37M — lighter than usual.
- Price is -7.7% vs its 50-day average ($0.72) and -31.9% vs its 200-day average ($0.97).
- 52-week range $0.63–$1.72; today's close sits at 3% of that range, 61.6% below the 52-week high.
Oct 9, 2026 — LAB rises 3.0% to $0.69
- Closed at $0.69, +2.99% vs the prior close of $0.67. Day range $0.66–$0.70, opened at $0.68.
- Volume was 649.20K shares, 0.5x its 50-day average of 1.43M — lighter than usual.
- Price is -4.1% vs its 50-day average ($0.72) and -29.1% vs its 200-day average ($0.97).
- 52-week range $0.63–$1.72; today's close sits at 6% of that range, 59.9% below the 52-week high.
Oct 8, 2026 — LAB dips 1.5% to $0.67, a 1-month low, 3 down days in a row
- Closed at $0.67, -1.47% vs the prior close of $0.68. Day range $0.64–$0.68, opened at $0.67.
- Volume was 1.91M shares, 1.3x its 50-day average of 1.48M.
- Price is -7.4% vs its 50-day average ($0.72) and -31.5% vs its 200-day average ($0.98).
- 52-week range $0.63–$1.72; today's close sits at 4% of that range, 61.0% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — LAB slides 5.6% to $0.68, a 1-month low
- Closed at $0.68, -5.56% vs the prior close of $0.72. Day range $0.68–$0.74, opened at $0.71.
- Volume was 1.39M shares, 0.9x its 50-day average of 1.51M.
- Price is -6.5% vs its 50-day average ($0.73) and -30.9% vs its 200-day average ($0.98).
- 52-week range $0.63–$1.72; today's close sits at 5% of that range, 60.5% below the 52-week high.
Oct 6, 2026 — LAB slides 5.3% to $0.72
- Closed at $0.72, -5.26% vs the prior close of $0.76. Day range $0.72–$0.80, opened at $0.77.
- Volume was 1.40M shares, 0.9x its 50-day average of 1.51M.
- Price is -1.3% vs its 50-day average ($0.73) and -27.1% vs its 200-day average ($0.99).
- 52-week range $0.63–$1.72; today's close sits at 8% of that range, 58.1% below the 52-week high.
Oct 5, 2026 — LAB rises 2.7% to $0.76
- Closed at $0.76, +2.70% vs the prior close of $0.74. Day range $0.74–$0.80, opened at $0.74.
- Volume was 1.18M shares, 0.8x its 50-day average of 1.51M.
- Price is +4.0% vs its 50-day average ($0.73) and -23.4% vs its 200-day average ($0.99).
- 52-week range $0.63–$1.72; today's close sits at 12% of that range, 55.8% below the 52-week high.
- SEC filings that day: 8-K.
Oct 2, 2026 — LAB rises 1.4% to $0.74
- Closed at $0.74, +1.37% vs the prior close of $0.73. Day range $0.73–$0.76, opened at $0.73.
- Volume was 786.50K shares, 0.5x its 50-day average of 1.55M — lighter than usual.
- Price is +1.1% vs its 50-day average ($0.73) and -25.7% vs its 200-day average ($1.00).
- 52-week range $0.63–$1.72; today's close sits at 10% of that range, 57.0% below the 52-week high.
LAB latest news & SEC filings
Every SEC filing by or about LAB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 1.02 — Ended a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 5, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $20.10M (prior year $21.76M) (-7.6% vs Jun 30, 2025)
- Net income: -$26.76M (prior year -$33.46M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.07 (prior year -$0.09) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade LAB
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 24, 2026, Jan 30, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.70% (largest 5.6%).
- Liquidity: about 874.66K shares (≈$550.16K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.63 vs a range of $0.63–$1.72 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Private Growth Equity Fund Gp, Llc Casdin bought 150,000 shares on Dec 4, 2025.
- Latest filings: 8-K Oct 5, 2026; 8-K Sep 30, 2026; 10-Q Aug 5, 2026.
- Share count: 392.58M shares outstanding (Aug 3, 2026), +2.8% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
LAB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.66 | 0.66 | 0.63 | 0.63 | 647.31K |
| Oct 15, 2026 | 0.63 | 0.67 | 0.63 | 0.66 | 485.70K |
| Oct 14, 2026 | 0.64 | 0.68 | 0.63 | 0.63 | 1.19M |
| Oct 13, 2026 | 0.66 | 0.67 | 0.65 | 0.66 | 368.90K |
| Oct 12, 2026 | 0.69 | 0.69 | 0.65 | 0.66 | 494.60K |
| Oct 9, 2026 | 0.68 | 0.70 | 0.66 | 0.69 | 649.20K |
| Oct 8, 2026 | 0.67 | 0.68 | 0.64 | 0.67 | 1.91M |
| Oct 7, 2026 | 0.71 | 0.74 | 0.68 | 0.68 | 1.39M |
| Oct 6, 2026 | 0.77 | 0.80 | 0.72 | 0.72 | 1.40M |
| Oct 5, 2026 | 0.74 | 0.80 | 0.74 | 0.76 | 1.18M |
| Oct 2, 2026 | 0.73 | 0.76 | 0.73 | 0.74 | 786.50K |
| Oct 1, 2026 | 0.74 | 0.75 | 0.72 | 0.73 | 1.08M |
| Sep 30, 2026 | 0.72 | 0.74 | 0.71 | 0.74 | 1.59M |
| Sep 29, 2026 | 0.73 | 0.73 | 0.71 | 0.71 | 173.40K |
| Sep 28, 2026 | 0.75 | 0.75 | 0.72 | 0.73 | 479.00K |
| Sep 25, 2026 | 0.74 | 0.75 | 0.71 | 0.74 | 471.80K |
| Sep 24, 2026 | 0.74 | 0.77 | 0.74 | 0.74 | 743.90K |
| Sep 23, 2026 | 0.75 | 0.77 | 0.73 | 0.74 | 653.40K |
| Sep 22, 2026 | 0.74 | 0.77 | 0.74 | 0.75 | 1.35M |
| Sep 21, 2026 | 0.76 | 0.76 | 0.73 | 0.74 | 459.60K |
About Standard Biotools
Standard Biotools (LAB) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1162194.
LAB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Private Growth Equity Fund Gp, Llc Casdin | Director | Dec 4, 2025 |
| Thomas D. Carey | Director | Jun 23, 2026 |
| Capital, Llc Casdin | Director | Dec 4, 2025 |
| Eli Casdin | Director | Jun 23, 2026 |
| Partners Gp, Llc Casdin | Director | Dec 4, 2025 |
| Partners Master Fund, L.P. Casdin | Director | Dec 4, 2025 |
| Private Growth Equity Fund Ii Gp, Llc Casdin | Director | Dec 4, 2025 |
| Private Growth Equity Fund Ii, L.P. Casdin | Director | Dec 4, 2025 |
| Private Growth Equity Fund, L.P. Casdin | Director | Dec 4, 2025 |
| Troy Cox | Director | Jun 23, 2026 |
| Fenel M Eloi | Director | Jun 23, 2026 |
| Michael Egholm | President & CEO | Aug 24, 2026 |
| Kathy L Hibbs | Director | Jun 23, 2026 |
| Frank Witney | Director | Jun 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Michael Egholm | President & CEO | Aug 24, 2026 |
| Hanjoon Alex Kim | Chief Financial Officer | Aug 24, 2026 |
| Sean Mackay | SVP & Chief Business Officer | Aug 24, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 4, 2025 | Private Growth Equity Fund Gp, Llc Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Private Growth Equity Fund Gp, Llc Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Partners Master Fund, L.P. Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Partners Master Fund, L.P. Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Capital, Llc Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Capital, Llc Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Private Growth Equity Fund, L.P. Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Private Growth Equity Fund, L.P. Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Partners Gp, Llc Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Partners Gp, Llc Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Private Growth Equity Fund Ii, L.P. Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Private Growth Equity Fund Ii, L.P. Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Eli Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Eli Casdin | Buy | 150,000 | $1.45 |
| Dec 4, 2025 | Private Growth Equity Fund Ii Gp, Llc Casdin | Buy | 150,000 | $1.45 |
LAB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $85.33M | $-74.90M | -0.20 | $-74.34M |
| Dec 31, 2024 | $91.01M | $-138.88M | -0.52 | $-143.45M |
| Dec 31, 2023 | $106.34M | $-74.66M | -0.94 | $-43.29M |
| Dec 31, 2022 | $97.95M | $-190.10M | -2.43 | $-89.37M |
| Dec 31, 2021 | $130.58M | $-59.24M | -0.78 | $-44.06M |
Latest balance sheet: total assets $627.22M, total liabilities $87.25M, cash $270.03M (as of Jun 30, 2026).
LAB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $0.78 |
| May 5, 2026 | 8-K Item 2.02 (results) | $0.98 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $1.15 |
| Jan 30, 2026 | 8-K Item 2.02 (results) | $1.40 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $1.54 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $1.19 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $1.28 |
| May 6, 2025 | 8-K Item 2.02 (results) | $1.06 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $1.17 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $2.06 |
| Oct 30, 2024 | 8-K Item 2.02 (results) | $1.88 |
| Jul 31, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on LAB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.